{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T09:33:08Z","timestamp":1761989588168,"version":"3.37.3"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,4,7]],"date-time":"2021-04-07T00:00:00Z","timestamp":1617753600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,4,7]],"date-time":"2021-04-07T00:00:00Z","timestamp":1617753600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100006396","name":"Alexion Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006396","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Ther"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1007\/s40121-021-00425-7","type":"journal-article","created":{"date-parts":[[2021,4,7]],"date-time":"2021-04-07T10:17:56Z","timestamp":1617790676000},"page":"1045-1054","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Pharmacokinetic and Pharmacodynamic Evaluation of Ravulizumab in Adults with Severe Coronavirus Disease 2019"],"prefix":"10.1007","volume":"10","author":[{"given":"Alanna C.","family":"McEneny-King","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan P. R.","family":"Monteleone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shamsah D.","family":"Kazani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephan R.","family":"Ortiz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,4,7]]},"reference":[{"issue":"1","key":"425_CR1","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1186\/s13054-020-03240-7","volume":"24","author":"SJ Tzotzos","year":"2020","unstructured":"Tzotzos SJ, Fischer B, Fischer H, Zeitlinger M. Incidence of ARDS and outcomes in hospitalized patients with COVID-19: a global literature survey. Crit Care. 2020;24(1):516.","journal-title":"Crit Care"},{"issue":"15","key":"425_CR2","doi-asserted-by":"publisher","first-page":"e140711","DOI":"10.1172\/jci.insight.140711","volume":"5","author":"A Java","year":"2020","unstructured":"Java A, Apicelli AJ, Liszewski MK, et al. The complement system in COVID-19: friend and foe? JCI Insight. 2020;5(15):e140711.","journal-title":"JCI Insight"},{"issue":"6","key":"425_CR3","doi-asserted-by":"publisher","first-page":"992 e3","DOI":"10.1016\/j.chom.2020.04.009","volume":"27","author":"EJ Giamarellos-Bourboulis","year":"2020","unstructured":"Giamarellos-Bourboulis EJ, Netea MG, Rovina N, et al. Complex immune dysregulation in COVID-19 patients with severe respiratory failure. Cell Host Microbe. 2020;27(6):992 e3-1000 e3.","journal-title":"Cell Host Microbe"},{"issue":"15","key":"425_CR4","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1093\/cid\/ciaa248","volume":"71","author":"C Qin","year":"2020","unstructured":"Qin C, Zhou L, Hu Z, et al. Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in Wuhan, China. Clin Infect Dis. 2020;71(15):762\u20138.","journal-title":"Clin Infect Dis"},{"key":"425_CR5","doi-asserted-by":"publisher","first-page":"3734","DOI":"10.1016\/j.csbj.2020.11.005","volume":"18","author":"R Tiwari","year":"2020","unstructured":"Tiwari R, Mishra AR, Mikaeloff F, et al. In silico and in vitro studies reveal complement system drives coagulation cascade in SARS-CoV-2 pathogenesis. Comput Struct Biotechnol J. 2020;18:3734\u201344.","journal-title":"Comput Struct Biotechnol J"},{"issue":"12","key":"425_CR6","doi-asserted-by":"publisher","first-page":"2847","DOI":"10.3324\/haematol.2020.260117","volume":"105","author":"R Peffault de Latour","year":"2020","unstructured":"Peffault de Latour R, Bergeron A, Lengline E, et al. Complement C5 inhibition in patients with COVID-19\u2014a promising target? Haematologica. 2020;105(12):2847\u201350.","journal-title":"Haematologica"},{"issue":"40","key":"425_CR7","doi-asserted-by":"publisher","first-page":"25018","DOI":"10.1073\/pnas.2010540117","volume":"117","author":"JC Holter","year":"2020","unstructured":"Holter JC, Pischke SE, de Boer E, et al. Systemic complement activation is associated with respiratory failure in COVID-19 hospitalized patients. Proc Natl Acad Sci USA. 2020;117(40):25018\u201325.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"7836","key":"425_CR8","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1038\/s41586-020-2600-6","volume":"588","author":"J Carvelli","year":"2020","unstructured":"Carvelli J, Demaria O, Vely F, et al. Association of COVID-19 inflammation with activation of the C5a\u2013C5aR1 axis. Nature. 2020;588(7836):146\u201350.","journal-title":"Nature"},{"key":"425_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.trsl.2020.04.007","volume":"220","author":"C Magro","year":"2020","unstructured":"Magro C, Mulvey JJ, Berlin D, et al. Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases. Transl Res. 2020;220:1\u201313.","journal-title":"Transl Res"},{"key":"425_CR10","doi-asserted-by":"publisher","first-page":"102560","DOI":"10.1016\/j.jaut.2020.102560","volume":"116","author":"M Cugno","year":"2021","unstructured":"Cugno M, Meroni PL, Gualtierotti R, et al. Complement activation and endothelial perturbation parallel COVID-19 severity and activity. J Autoimmun. 2021;116:102560.","journal-title":"J Autoimmun"},{"issue":"11","key":"425_CR11","doi-asserted-by":"publisher","first-page":"4417","DOI":"10.1021\/acs.jproteome.0c00365","volume":"19","author":"A D'Alessandro","year":"2020","unstructured":"D\u2019Alessandro A, Thomas T, Dzieciatkowska M, et al. Serum proteomics in COVID-19 patients: altered coagulation and complement status as a function of IL-6 level. J Proteome Res. 2020;19(11):4417\u201327.","journal-title":"J Proteome Res"},{"issue":"10","key":"425_CR12","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1038\/s41591-020-1021-2","volume":"26","author":"V Ramlall","year":"2020","unstructured":"Ramlall V, Thangaraj PM, Meydan C, et al. Immune complement and coagulation dysfunction in adverse outcomes of SARS-CoV-2 infection. Nat Med. 2020;26(10):1609\u201315.","journal-title":"Nat Med"},{"issue":"23","key":"425_CR13","doi-asserted-by":"publisher","first-page":"6051","DOI":"10.1182\/bloodadvances.2020003471","volume":"4","author":"C Diorio","year":"2020","unstructured":"Diorio C, McNerney KO, Lambert M, et al. Evidence of thrombotic microangiopathy in children with SARS-CoV-2 across the spectrum of clinical presentations. Blood Adv. 2020;4(23):6051\u201363.","journal-title":"Blood Adv"},{"issue":"5","key":"425_CR14","doi-asserted-by":"publisher","first-page":"e01753-18","DOI":"10.1128\/mBio.01753-18","volume":"9","author":"LE Gralinski","year":"2018","unstructured":"Gralinski LE, Sheahan TP, Morrison TE, et al. Complement activation contributes to severe acute respiratory syndrome coronavirus pathogenesis. mBio. 2018;9(5):e01753-18.","journal-title":"mBio"},{"issue":"1","key":"425_CR15","first-page":"77","volume":"7","author":"Y Jiang","year":"2018","unstructured":"Jiang Y, Zhao G, Song N, et al. Blockade of the C5a\u2013C5aR axis alleviates lung damage in hDPP4-transgenic mice infected with MERS-CoV. Emerg Microbes Infect. 2018;7(1):77.","journal-title":"Emerg Microbes Infect"},{"key":"425_CR16","doi-asserted-by":"publisher","first-page":"100590","DOI":"10.1016\/j.eclinm.2020.100590","volume":"28","author":"D Annane","year":"2020","unstructured":"Annane D, Heming N, Grimaldi-Bensouda L, et al. Eculizumab as an emergency treatment for adult patients with severe COVID-19 in the intensive care unit: a proof-of-concept study. EClinicalMedicine. 2020;28:100590.","journal-title":"EClinicalMedicine"},{"issue":"7","key":"425_CR17","first-page":"4040","volume":"24","author":"F Diurno","year":"2020","unstructured":"Diurno F, Numis FG, Porta G, et al. Eculizumab treatment in patients with COVID-19: preliminary results from real life ASL Napoli 2 Nord experience. Eur Rev Med Pharmacol Sci. 2020;24(7):4040\u20137.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"425_CR18","doi-asserted-by":"publisher","first-page":"108555","DOI":"10.1016\/j.clim.2020.108555","volume":"219","author":"J Laurence","year":"2020","unstructured":"Laurence J, Mulvey JJ, Seshadri M, et al. Anti-complement C5 therapy with eculizumab in three cases of critical COVID-19. Clin Immunol. 2020;219:108555.","journal-title":"Clin Immunol"},{"issue":"4","key":"425_CR19","doi-asserted-by":"publisher","first-page":"e0195909","DOI":"10.1371\/journal.pone.0195909","volume":"13","author":"D Sheridan","year":"2018","unstructured":"Sheridan D, Yu ZX, Zhang Y, et al. Design and preclinical characterization of ALXN1210: a novel anti-C5 antibody with extended duration of action. PLoS One. 2018;13(4):e0195909.","journal-title":"PLoS One"},{"key":"425_CR20","volume-title":"Ultomiris\u00ae (ravulizumab-cwvz) prescribing information","author":"United States Food and Drug Administration","year":"2019","unstructured":"United States Food and Drug Administration. Ultomiris\u00ae (ravulizumab-cwvz) prescribing information. Boston: Alexion Pharmaceuticals; 2019."},{"issue":"3","key":"425_CR21","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1111\/bjh.16711","volume":"191","author":"R Peffault de Latour","year":"2020","unstructured":"Peffault de Latour R, Brodsky RA, Ortiz S, et al. Pharmacokinetic and pharmacodynamic effects of ravulizumab and eculizumab on complement component 5 in adults with paroxysmal nocturnal haemoglobinuria: results of two phase\u00a03 randomised, multicentre studies. Br J Haematol. 2020;191(3):476\u201385.","journal-title":"Br J Haematol"},{"issue":"6","key":"425_CR22","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1016\/j.kint.2020.01.035","volume":"97","author":"E Rondeau","year":"2020","unstructured":"Rondeau E, Scully M, Ariceta G, et al. The long-acting C5 inhibitor, ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naive to complement inhibitor treatment. Kidney Int. 2020;97(6):1287\u201396.","journal-title":"Kidney Int"},{"issue":"1","key":"425_CR23","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1186\/s13063-020-04548-z","volume":"21","author":"K Smith","year":"2020","unstructured":"Smith K, Pace A, Ortiz S, Kazani S, Rottinghaus S. A phase\u00a03 open-label, randomized, controlled study to evaluate the efficacy and safety of intravenously administered ravulizumab compared with best supportive care in patients with COVID-19 severe pneumonia, acute lung injury, or acute respiratory distress syndrome: a structured summary of a study protocol for a randomised controlled trial. Trials. 2020;21(1):639.","journal-title":"Trials"},{"key":"425_CR24","unstructured":"Alexion Pharmaceuticals Inc. NDA\/BLA multi-disciplinary review and evaluation BLA 761108. Ultomiris (ravulizumab) 2018. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2018\/761108Orig1s000MultidisciplineR.pdf. Accessed 30 Oct 2020."},{"key":"425_CR25","doi-asserted-by":"publisher","first-page":"2664","DOI":"10.3389\/fimmu.2018.02664","volume":"9","author":"M Gaya da Costa","year":"2018","unstructured":"Gaya da Costa M, Poppelaars F, van Kooten C, et al. Age and sex-associated changes of complement activity and complement levels in a healthy caucasian population. Front Immunol. 2018;9:2664.","journal-title":"Front Immunol"},{"issue":"9","key":"425_CR26","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/S2213-2600(20)30316-7","volume":"8","author":"C Karagiannidis","year":"2020","unstructured":"Karagiannidis C, Mostert C, Hentschker C, et al. Case characteristics, resource use, and outcomes of 10 021 patients with COVID-19 admitted to 920 German hospitals: an observational study. Lancet Respir Med. 2020;8(9):853\u201362.","journal-title":"Lancet Respir Med"}],"container-title":["Infectious Diseases and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-021-00425-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40121-021-00425-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-021-00425-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,12]],"date-time":"2021-05-12T19:28:34Z","timestamp":1620847714000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40121-021-00425-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,7]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["425"],"URL":"https:\/\/doi.org\/10.1007\/s40121-021-00425-7","relation":{},"ISSN":["2193-8229","2193-6382"],"issn-type":[{"type":"print","value":"2193-8229"},{"type":"electronic","value":"2193-6382"}],"subject":[],"published":{"date-parts":[[2021,4,7]]},"assertion":[{"value":"2 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}